BioSIM 抗人 PCSK9 抗体 (伊努西单抗)，生物类

BioSIM 抗人 PCSK9 抗体 (伊努西单抗) - 专业科研试剂

产品名称：BioSIM anti-Human PCSK9 Antibody (Ebronucimab Biosimilar), Research Grade

产品概述

BioSIM 抗人 PCSK9 抗体是一种高特异性研究级生物类似药，针对人源PCSK9蛋白设计。该抗体在无动物成分的生产环境中制备，采用先进的体外无蛋白细胞培养技术，经过严格的多步纯化工艺，确保产品纯度和活性。适用于多种研究应用，包括ELISA、流式细胞术(FACS)、功能检测及体内研究。

产品信息

• 供应商：InvivoCrown
• 产品货号：SIM0541-5mg
• 产品规格：5mg
• CAS号：2304800-90-4
• 产品类型：二抗
• 来源宿主：Human
• 反应性：Human

背景资料

PCSK9(前蛋白转化酶枯草杆菌蛋白酶/kexin 9型)是胆固醇代谢调节的关键因子，通过降解肝细胞表面的LDL受体影响血浆低密度脂蛋白胆固醇(LDL-C)水平。伊努西单抗作为PCSK9抑制剂，能够特异性结合PCSK9，阻断其与LDL受体的相互作用，从而增加LDL受体的表达，降低血液中的胆固醇水平。

该生物类似抗体在无动物成分的设施中生产，仅使用体外的无蛋白细胞培养技术，确保了产品的高度一致性和安全性。经过多步骤的纯化过程，其中包括采用Protein A或G的色谱工艺，最大限度减少了杂质和宿主蛋白残留。

研究领域

该抗体主要应用于原发性高胆固醇血症的研究，也可用于其他与脂质代谢紊乱相关的研究领域。

应用类型

• ELISA：可用于PCSK9蛋白的定量检测
• FACS：适用于流式细胞术检测细胞表面PCSK9表达
• Functional assay：可用于功能研究，评估抗体对PCSK9生物活性的影响
• Research in vivo：适用于动物模型研究，探索PCSK9在体内的生物学功能

保存建议

为确保抗体活性和稳定性，请遵循以下保存条件：

• 避免反复冻融，以防止蛋白降解
• 短期需求（1-2周）：请在4°C下保存
• 中长期保存（最长12个月）：请在-20°C下保存
• 长期储存：建议在-80°C条件下保存

注意事项

该产品的免疫原性信息请参考产品说明书。建议在使用前进行适当的验证实验，以确保抗体在特定实验条件下的适用性。本产品仅供科研使用，不可用于临床诊断或治疗。

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

BioSIM Anti-Human PCSK9 Antibody (Ebronucimab Biosimilar) - Professional Research Reagent

Product Name: BioSIM anti-Human PCSK9 Antibody (Ebronucimab Biosimilar), Research Grade

Product Overview

BioSIM Anti-Human PCSK9 Antibody is a highly specific research-grade biosimilar designed for human PCSK9 protein. The antibody is prepared in an animal component-free production environment using advanced serum-free in vitro cell culture technology, and undergoes a rigorous multi-step purification process to ensure product purity and activity. Suitable for various research applications including ELISA, Flow Cytometry (FACS), functional assays, and in vivo studies.

Product Information

• Supplier: InvivoCrown
• Catalog Number: SIM0541-5mg
• Specification: 5mg
• CAS Number: 2304800-90-4
• Product Type: Secondary Antibody
• Source Host: Human
• Reactivity: Human

Background

PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) is a key regulator of cholesterol metabolism, affecting plasma low-density lipoprotein cholesterol (LDL-C) levels by degrading LDL receptors on hepatocyte surfaces. As a PCSK9 inhibitor, Ebronucimab specifically binds to PCSK9, blocking its interaction with LDL receptors, thereby increasing LDL receptor expression and reducing cholesterol levels in the blood.

This biosimilar antibody is produced in animal component-free facilities using only in vitro serum-free cell culture technology, ensuring high product consistency and safety. The multi-step purification process, including chromatography with Protein A or G, minimizes impurities and host protein residues.

Research Areas

This antibody is primarily used for research on Familial Hypercholesterolemia, and can also be applied to other research areas related to lipid metabolism disorders.

Application Types

• ELISA: Suitable for quantitative detection of PCSK9 protein
• FACS: Applicable for flow cytometry detection of cell surface PCSK9 expression
• Functional assay: Can be used for functional studies to evaluate the effect of the antibody on PCSK9 biological activity
• Research in vivo: Suitable for animal model studies to explore the biological functions of PCSK9 in vivo

Storage Recommendations

To maintain antibody activity and stability, please follow the storage conditions below:

• Avoid repeated freeze-thaw cycles to prevent protein degradation
• Short-term requirement (1-2 weeks): Store at 4°C
• Medium to long-term storage (up to 12 months): Store at -20°C
• Long-term storage: Recommended at -80°C

Precautions

Please refer to the product manual for immunogenicity information of this product. It is recommended to perform appropriate validation experiments before use to ensure the suitability of the antibody under specific experimental conditions. This product is for research use only and is not intended for diagnostic or therapeutic purposes.

Note: The above information may change due to factors such as product optimization and upgrades. For specific information, please consult Yacoin Biotechnology.